Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Sarraju, A; Li, JW; Cannon, CP; Chang, TI; Agarwal, R; Bakris, G; Charytan, DM; de Zeeuw, D; Greene, T; Heerspink, HJL; Levin, A; Neal, B; Pollock, C; Wheeler, DC; Yavin, Y; Zhang, H; Zinman, B; Perkovic, V; Jardine, M; Mahaffey, KW

Mahaffey, KW (corresponding author), Stanford Ctr Clin Res, 300 Pasteur Dr, Stanford, CA 94305 USA.

AMERICAN HEART JOURNAL, 2021; 233 (): 141

Abstract

We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failu......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索